Shots:
- TScan signs exclusive research and option to license agreement with Qiagen to develop T cell-based laboratory tests for detecting prior exposure to the SARS-CoV-2
- Qiagen gets an option to license the rights and IP for several of TScan discovered immunodominant T cell targets, associated sequences and relevant data for the development and commercialization of IVD tests. In advance of exercising its option, Qiagen has the right to evaluate TScan’s discoveries
- The targeted immunodominant were identified through the T-Scan TCR/Target discovery platform enabling the mapping of the specific epitopes in SARS-CoV-2
Click here to read full press release/ article | Ref: Businesswire | Image: TrialSite News
The post Qiagen Collaborate with TScan to Develop T Cell-Based COVID-19 Test first appeared on PharmaShots.
